Designing for Home Networking 2...$1.5 billion market for wireline Home Networking silicon by 2011 Total WW IPTV subs will grow from 13m in 2007 to 103m in 2011 Source: iSupply, April

5 March 2009

Designing for Home Networking 2.0

TFV Investors Meeting

5 March 2009CONFIDENTIAL// CopperGate Communications, Inc.

2

CopperGate at a Glance

Franchise company in large and growing home networking marketPublic company when market conditions will improve

Goals

CFBE and Profitable for the past 2 yearsSustainable business model

Financial Results

Headcount of ~100, with 2/3 in R&D, 1/3 in sales/support/otherTeam

>30 operators around the globe spanning Tier 1/2/3 carriers End Customers

>30 network equipment manufacturers around the globeCustomer Base

3 generations of ITU HPNA ICs since 05; 24 core patentsOver 8 million ICs shipped; Coppergate IC installed every 7.5 secondsFirst HomePlug AV IC ships in H209 to broaden TAM

Products

Telco IPTV: 13M subs wwide; growing to 103M by 2011DSL/FTTx: over 300M subs wwide; grown by 30% last year

Market Opportunity

Leading Provider of Home Networking Semiconductor DevicesBusiness


3

Company History and Milestones

CopperGate started its operations

HPNA 3.0 Approved (240Mbps)

First HPNA 3.0 products announced

ITU approves G.9954–2004 (240Mbps)

2000 2003 2004 2005 2006 2007 2008

AT&T selects HPNA for

Lightspeed

HPNA 3.1 approved (320Mbps)

ITU approves G.9954-2007 (320Mbps)

Firstprofitable year

CopperGate acquires

HomePlug AV

AT&TStarts

deployment

ITU approves G.hn

foundation spec


4

160MbpsCG3110

2006 2008 20092007

128MbpsCG3010 320MbpsCG3210 256MbpsCG3310

PLC – HPAV200MbpsCG2110

2010

- Coax/TP/Powerline- 1Gbps- Backward compatibleWith HPNA and HPAV

CG4110

HPAV

G.HN

HPNA

Compatible with next generation HPNA and ITU G.HN Standards

Low cost single chip

HPNA 3/ITU G.9954

PRODUCT ROADMAPProducts & Roadmap


5

IP-STB Residential Gateway Ethernet Bridges

iNID ONT Test EquipmentMDU

2Wire, Alcatel Lucent, Motorola, Gemtek, Xavi, Sendtek, Billion, SMC, Hitron, Scientific Atlanta

Entone

Sendtek

Tii

Ineoquest2Wire, Zhone, Allied, Telesyn, Tii, Calix, Occam, Pannaway, Arcadian

EoC End PointEoC Master

End Products Using CG Silicon


6

Over 30 Direct Customers


7

Over 30 Operator End Customers

AT&T U-verse is our largest end customer, but many others deploying HPNALargest footprint in North AmericaCopperGate HPNA wins on performance, price, power, ease of use


8Experienced Team With History of Success

Gabi Hilevitz CEO

William (Bill) Simmelink President CopperGate Inc.

David Baum VP Marketing & Co-Founder

Nurit Benjamini CFO

Tzach Schwartz VP R&D

Rami Verbin CTO __________________________

Rami Kopelman VP Business Development Europe and Asia


9

Battle for Connected Home

Dramatic growth in broadband connectivity and bandwidthTelco’s attacking cable TV marketCable attacking telephony business

Digital Convergence

Rapid adoption of High Definition TV and PVRs

Convergence of computing, telephony and TV

Need to distribute content across home in reliable, standard, efficient and cost-effective manner

Market Drivers


10

Interconnect Device Shipments

0

50

100

150

200

250

2005 2006 2007 2008 2009 2010 2011

Large and Growing Market Opportunity

Over 600M wireline network nodes will ship in next 3 years $1.5 billion market for wireline Home Networking silicon by 2011 Total WW IPTV subs will grow from 13m in 2007 to 103m in 2011

Source: iSupply, April 2007

Silicon TAM

$0$200$400$600$800

$1,000$1,200$1,400$1,600$1,800

2005 2006 2007 2008 2009 2010 2011

M

M

M

M

M

M


11

11

Telco’s Triple Play


12Success Story - AT&T U-verse

AT&T U-verse Roll-out • New portfolio of integrated digital TV,

high speed Internet and voice services

• Engaged with Alcatel, Microsoft, Motorola, Scientific Atlanta, & 2Wire

• 17 million homes passed by Q408/e, 30 million homes passed by 2011/e

• 1,045K subscribers by Q408/e and growing

• Available in 82 markets across 16 states

CopperGate's Role• CopperGate is the sole provider of chips for in-home distribution of video

• Penetration is 4-6 chips/subscriber


13MDU Broadband Access

IP Services to Multiple Dwelling Units

CopperGate Confidential Information


14

The Wired Home Networking Battle

HPNA3CopperGate

HPNA3CopperGate2005

2009

2012

Coax Phone PowerLine

MoCA1Entropic

HomePlugIntellon

MoCA1Entropic, BRCM

HomePlugIntellon, CopperGate

ITU-G.hnCopperGate, Intellon? Ikanos?

DS2? Gigle? TI? Intel? ST? IFX?

MoCA2Entropic?, BRCM


15

2004 2005 2006 2007 2008 2009E

Revenues Net Profit

Financial Highlights

Fabless semiconductor companyScalable business modelStrong revenue growthSustainable gross marginProfitable since 2007Accelerating cash generation


16

SUMMARY

Market leader with the highest performing home network solutionsOnly silicon company supporting all three wire typesWidest offering including HomePNA, HomePlug AV, and soon, G.hnStrong revenue growthSustainable gross marginOpportunity to become the dominant home networking franchise


17


17

Thank You

February 2009

Confidential proprietary data MGVS

MGVS - Snapshot

Promising results in PI/IIa study in no-option patients

Four product groups with strong IP position

Potential collaboration with a major player

Proven operational capabilities in two continents

Approved IND’s for two products, Initial PEI (Germany) Approval for 1 product

Unique, devoted and capable team

Proprietary Technology

Manufactures cell based product that support the growth of new arteries

Utilizes cells and proteins that are operative in the natural development and maintenance of the arterial tree

Leading products include:■ MultiGeneAngio – endothelial cells and smooth muscle cells modified with

the Ang-1 and VEGF gene respectively

■ MultiGeneGraft – surgical graft coated with endothelial cells modified with VEGF and adhesion genes

MGVS Products: Current Status and

Development Program

ProgramProduct in

development

Research /

preclinical

development

Phase I/IIa Phase IIb

PAD - Angiogenesis MultiGeneAngio

PAD – Bypass grafts MultiGeneGraft

CAD - Angiogenesis MultiGeneAngio

AV Access graft MultiGeneGraft Dialysis

CAD – Clot resistant stent

MultiGeneStent

Liver disease MultiGeneLiver

Diabetic eyeMultiGene DiabeticEye

MultiGeneAngio

Therapeutic objective: alleviate ischemia in peripheral arterial disease & cardiac arterial disease patients

Utilizes the patient’s gene-modified cells

Efficacy study shows improved blood flow after treatment

with MultiGeneAngio when compared to each cell type alone or cells without genes

MultiGeneAngio

100%

80%

60%

40%

20%

0%Control

(n=18)

MGA ther.

(n=17)

Naïve + LacZ

(n=16)

ECang

(n=14)

SMCvegf

(n=12)

Rt. To Lt. CFA Blood flow ratio (Aver±SD, p<0.001)

MGA (MultiGeneAngio) significantly* improved perfusion in rabbit hind limb model of ischemia in comparison to endothelial cells (ECAng Ther), Smooth muscle cells (SMCvegf ther), saline injection (control) or naive +lac Z cell combination (untransduced cells or cells transduced with marker gene).

MultiGeneAngio: Arteriogenesis in a Rabbit PAD Model at 6 Months

New Arteries

New Arteries

Control Treated


Smooth Technology Transfer to

Top US Centers

Study highlights

“you must treat my other leg” Patient #5 (from Philadelphia)

“The only time I have seen such a dramatic

improvement was after

successful bypass surgery

or balloon or stent ” Dr. M. Grossman from Ann Arbor on the improvement of the first two patients

Angiogram of patient #2 at 1 year follow up showing an occluded stent and bypass graft and a robust collateral arteries after therapy (“enhanced natural

bypass”)

The need for MGG - bypass surgery

Occluded artery

Bypass graft

Current failure rates PVD synthetic grafts:

42-73% after 3 years due to scar formation (neointima proliferation) and clotting

MultiGeneGraft: Polymer Graft Lined with Endothelial Cells

Polymer graft


Angiography at 6 months show that MultiGeneGraftimproved graft patency in comparison to control graft

MultiGeneGraft

NaiveNaiveBareBare

dual genesdual genes

EC expressing dual genes (n=6)

1/6

naive endothelial Cells (n=6)

4/6

ePTFE bare grafts(n=6)

5/6

Type of cellsseeded

Total occlusion


Management Team

Guy Yachin, CEO

■ Former CEO of Chiasma Inc., Naiot Technological Center

■ Initiated the establishment of biomedical companies such as

Remon, Enzymotec, NanoPass

Moshe Flugelman, President & CTO

■ The founder of MGVS, based on research started in 1989

■ An interventional cardiologist and a faculty at Carmel Medical Center

and the Technion

Ranny Yaffe, CFO

■ Former CFO of BioShaf and BioPreventive

Board of Directors

Benjamin Zeevi, Chairman of the board■ Managing General Partner, Tamir Fishman Ventures

Yoav Chelouche

■ Managing General Partner, Aviv Ventures

Yoav Doppelt■ CEO, The Ofer Hitech Group

Azin Parhizgar■ Formerly Medtronic and COO of Conor Medsystems

Moshe Flugelman

Guy Yachin

MGVS quadruple market opportunity

Cell-based products Time to market or Deal

Intellectual Property

Required funds for Strategy

Market:Patients (US)

Market: Overall $ (US)

MGVS’ Strategy

Angiogenesis opportunity – PAD 2-3 years Eu + $20m 225K 7.8B1 Complete pivotal

Angiogenesis - CAD 2 years Eu + $0.8m 650K 22B1 Collaborate early

1Overall Market, 2Annual Market,

Tissue engineering products

Biosynthetic graft - PAD 1.5-2 years US + $2.5m 24K 720M2 Collaborate (PI/IIa)

Biosynthetic graft - Dialysis 2 years US + TBD 63K 940M2 TBD

Protein – based products

Protein eluting stent 2 years US + $0.8m 1.6M 320M2 Collaborate early

Organ regeneration products

Liver regeneration 2 years EU, USA+ $0.5m 12K 1.2B2 Collaborate early

Intellectual Property Protection

for Multiple Applications

Strong patent position covering all fields of core technology, as well as current and future products and business model (6 core patents application). Portfolio is managed by the Boston office of Mintz, Levin

Two US patents granted,

7,364,725 Endothelial cells engineered to express or overexpress fibulin-5 and a growth factor

7,175,658 Artificial vascular grafts, their construction and use

Claims of two additional applications granted allowance (liver regeneration, biological stent)

One European patent granted

Nucleic acid constructs, vascular cells transformed therewith, pharmaceutical compositions and methods utilizing same for inducing angiogenesis

Claims of additional application granted allowance (liver regeneration)

Regulatory plan

A second phase I/IIa study in Critical Limb Ischemia (12 patients, 3 months flow up, two doses)

Primary endpoint: safety

Secondary endpoint: efficacy

Pivotal study Critical Limb Ischemia: 150 patients, 6 months follow up

Primary endpoint: efficacy (relief of pain, wound healing)

Israel, US, and Germany

Conclusions

Therapeutic breakthrough products addressing very large markets for no option patients

Great investment opportunity with rapid entry to multiple markets

Impressive pipeline with quadruple market opportunity

Encouraging results in Phase I/IIa studies

Attractive Business model

Clear and rapid regulatory pathway

1

VoltaireVoltaireVoltaireCompany OverviewCompany Overview

March 2009March 2009

Ronnie KennethChief Executive Officer

© 2009 Voltaire, Ltd.. 2

Safe HarborSafe Harbor

Certain statements in this presentation relate to future results that are forward-looking statements.

This presentation contains statements involving risks and uncertainties, including statements relating to Voltaire’s

market opportunity and future business prospects. Actual results may differ materially and reported results

should not be considered as an indication of future performance. Factors that could cause actual results to

differ are included in Voltaire’s Form 20-F.

Trademarks which appear in this presentation belong to their respective owners.


Voltaire (NASDAQ: VOLT) - BackgroundVoltaire (NASDAQ: VOLT) - Background

Leading provider of scale-out data center fabrics- Used by more than 30% of Fortune100 companies

- Worldwide locations; ~185 employees

Generated 2008 YoY revenue growth- 16% YoY reaching $62 million

Healthy cash balance to fuel growth strategy- $55 million of cash end Q4-08

Announced several key products and partnerships in 2008


What is Scale-out Computing?What is Scale-out Computing?

The ability to build large data centers that scale horizontally to thousands of servers while:

- Leveraging industry standard servers, storage and fabrics

- Delivering highly dense and power efficient infrastructure

- Enabling applications to accelerate performance while scaling out in resources


Voltaire Unique Value PropositionScale-out Computing Fabric for Data CentersVoltaire Unique Value PropositionScale-out Computing Fabric for Data Centers

Performance Efficiency

ApplicationAcceleration

Data CenterScale-out

High PerformanceScale-out Fabrics

Platforms and Software


Voltaire – The Data Center Pure PlayVoltaire – The Data Center Pure Play

Ethernet / Fibre Channel Network

The Scale-out Data Center

WAN


Successful Growth StrategySuccessful Growth Strategy

Premier OEM Go-To-Market Strategy

Vertical Solutions Approach

EnergyFinancial

Government Manufacturing

Entertainment Life Sciences

Differentiated Products


Fabric & I/O Management Software

Voltaire Product PortfolioEnd-to-end Scale-out Fabric SolutionsVoltaire Product PortfolioEnd-to-end Scale-out Fabric Solutions

Application AccelerationSoftware

Server Fabric and I/O Virtualization Hardware

Data Centers CloudsClusters


Innovating with new 40Gbps Platforms and Software Innovating with new 40Gbps Platforms and Software

UFM Unified Fabric Manager

Grid Director 4700

Just

Announced

Grid Director 4036

Already

Shipping


Delivering Scale-out Fabrics Across Industries Delivering Scale-out Fabrics Across Industries

Scaling Out Oracle ExadataDatabases and Storage

Powering theWorld LargestSupercomputer

Scaling Out Audi’s CAE Applications

Scaling-out JPMorgan’s Compute Backbone

11

Financial HighlightsFinancial Highlights


Revenue and Gross Margin Evolution (m. US$)Revenue and Gross Margin Evolution (m. US$)

Gross Margin

* Gross Margin on a Non-GAAP basis, please refer to the end period financial release for the full reconciliation

Q4

Q3

Q2

Q1


Financial Statement HighlightsFinancial Statement Highlights

Q4’ 07Q4’ 0820072008M. US$

17.413.253.161.6Revenues

47.8%55.5%42.6%53.1%Gross Margin*

0.7(1.9)(2.2)(1.7)Op. Profit (Loss)

1.4(1.7)(1.5)(0.9)Net Income*

59.655.8Ending Cash Balance

61.759.6Shareholders’ Equity

- Available cash includes cash, cash equivalents and marketable securities as at the end of the quarter* On a Non-GAAP basis, please refer to the end period financial release for the full reconciliation


In SummaryIn Summary

Three-Pronged Long-Term Growth Strategy

Substantial Business Developments in 2008

Healthy Cash Position Creates Opportunities

• Differentiated Vertical Markets approach• Premier Go-to-Market Partners• Innovative and Market Leading products

• Oracle\HP Launched New Database Machine based on Voltaire InfiniBand• GA of 40 Gbps QDR InfiniBand switching platform • Developing of new 40 Gb/s switch for IBM BladeCenter

• December ending cash balance $55 million with zero debt

15

Thank YouThank YouThank You

Ronnie KennethChief Executive Officer

Documents

Designing for Home Networking 2...$1.5 billion market for wireline Home Networking silicon by 2011 Total WW IPTV subs will grow from 13m in 2007 to 103m in 2011 Source: iSupply, April